The European Food Safety Authority (EFSA) has published an opinion that Arla Foods Ingredients’ Peptigen® IF-3080 (protein hydrolysate) is safe and suitable for use in infant formula and follow-on formula products in the EU.
The opinion has been published following EU regulations, which stated that from February 22, 2022, the nutritional safety and suitability of all protein hydrolysates used in the manufacture of infant milk formula and follow-on formula in the EU would need to be evaluated.
The company revealed that to date, Arla Foods Ingredients’ Peptigen IF-3080 is one of only a few milk protein hydrolysate ingredients to receive a positive EFSA opinion. Those which are not approved are removed from the market
The European Commission is expected to include Peptigen® IF-3080 in the Commission Delegated Regulation (EU) 2016/17 within the coming 12 months.
This means that the Arla Foods Ingredients’ Peptigen® IF-3080 will be approved for use in infant and follow-on formulas sold in the EU.
Until then, Arla Foods Ingredients can supply Peptigen® IF-3080 to its EU customers for the development of infant formula brands, which can be prepared for launch.
Anders Steen Jørgensen, Head of SBU Pediatric, Arla Foods Ingredients, said: “We are delighted by this opinion, which supports our reputation for having the industry’s highest levels of quality, innovation and food safety.”
Arla Foods Ingredients is a 100% owned subsidiary of Arla Foods.
In August 2020, Arla Foods Ingredients launched the first micellar casein isolate called MicelPure to come in standard and organic versions to help manufacturers meet demand for organic, natural and functional protein products.
Last month, Arla Foods UK boss Ash Amirahmadi claimed farmers should be at the centre of any plans to address sustainability and climate change.